Showing 20 of 41 recruiting trials for “juvenile-myelomonocytic-leukemia”
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
👨⚕️ Leland Metheny, MD, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center📍 1 site📅 Started Feb 2025View details ↗
Oral-ATO for TP53-mutated Myeloid Malignancies
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
👨⚕️ Alexandra M Stevens, Pediatric Early Phase Clinical Trial Network📍 18 sites📅 Started Feb 2025View details ↗
Daunorubicin + Cytarabine + Venetoclax in de Novo AML
👨⚕️ ZhangBiao Long, Doctor, Department of Hematology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road📍 1 site📅 Started Feb 2025View details ↗
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Revumenib in Combination With 7+3 + Midostaurin in AML
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
RecruitingNCT06439199 ↗
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
👨⚕️ Jianxiang Wang, M.D., Hematology Hospital of the Chinese Academy of Medical Sciences📍 6 sites📅 Started Jun 2024View details ↗
RecruitingNCT06111612 ↗
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
👨⚕️ Xianmin Song, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Jan 2024View details ↗
Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia
👨⚕️ Eduardo M Rego, MD PhD, Instituto do Cancer do Estado de Sao Paulo📍 1 site📅 Started Oct 2023View details ↗
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
👨⚕️ Huiying Qiu, PhD, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Mar 2023View details ↗
Page 1 of 3Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →